BioSpace News Archive

Business

Amidst Restructuring, Ambrx Doses First Patient with Anti-CD70 ADC

An anti-CD70 antibody drug conjugate developed by Ambrx, Inc. has been administered to the first patient in a Phase I study in China. It marks the first ADC in active development that targets CD70.

November 10, 2022
·
3 min read
·
Alex Keown
Business

Movers & Shakers: Odyssey, Daiichi Sankyo, Atsena and More

While Biogen and Seagen made the biggest C-suite splashes this week, other companies across the biopharma industry also bolstered their leadership teams with new talent.

November 10, 2022
·
6 min read
·
Alex Keown
iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the

November 10, 2022
·
10 min read
iBio Reports Fiscal Third Quarter 2022 Financial Results and Provides Corporate Update

BRYAN, Texas, May 12, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System,

November 10, 2022
·
15 min read
iBio Demonstrates Efficacy of an IL-2 Sparing Anti-CD25 Antibody Produced Using its FastPharming System for Treg Depletion in Cancer

Preclinical Data Presented at Frontiers in Cancer Immunotherapy 2022 Shows Potent Antibody-Dependent Cellular Cytotoxicity with Afucosylated Plant-Made Molecule

November 10, 2022
·
4 min read
Policy

AAV9-Based Gene Therapy for ALS Scores FDA Orphan Drug Nod

A gene therapy being developed by Eikonoklastes Therapeutics to treat ALS received Orphan Drug Designation, the company announced Wednesday.

November 10, 2022
·
3 min read
·
Heather McKenzie
Drug Development

AstraZeneca Scraps Three Early-Stage Programs, US COVID-19 Vaccine Efforts

AstraZeneca will give up on seeking approval for its COVID-19 vaccine in the United States. It is also abandoning three early-stage programs.

November 10, 2022
·
2 min read
·
Mark Terry
Business

Former Sanofi CEO Christopher Viehbacher Tapped as New Biogen Boss

GSK and Sanofi veteran Christopher A. Viehbacher will take over as chief executive officer for Biogen. He replaces Michel Vounatsos, whose departure was announced in May.

November 10, 2022
·
2 min read
·
Alex Keown
iBio to Participate in the H.C. Wainwright Global Investment Conference

BRYAN, Texas, May 18, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable, plant-based FastPharming® Manufacturing System,

November 10, 2022
·
1 min read
Business

Seagen Begins New Chapter with Novartis Vet David Epstein at the Helm

After six months of searching for its next chief executive, Washington’s largest biotech firm has found its match. On Thursday, Seagen named David R. Epstein as CEO.

November 10, 2022
·
2 min read
·
Kate Goodwin